Antineoplastics (immune checkpoint inhibitors / ICIs)
- Release T-cell inhibition against cancer
- PD-1/PD-L1 and CTLA-4 are major targets
- Can produce durable responses across tumors
- Toxicity = autoimmune inflammation
- skin, gut, lung, liver, endocrine organs
- Steroids treat many significant immune AEs
- Effects/toxicity can persist after drug stops
Class at a glance
- Release T-cell inhibition against cancer
Practical pearls
- PD-1/PD-L1 and CTLA-4 are major targets
Clinical role
- Can produce durable responses across tumors
- Steroids treat many significant immune AEs
Safety / monitoring
- Toxicity = autoimmune inflammation
- skin, gut, lung, liver, endocrine organs
- Effects/toxicity can persist after drug stops
Self-check
- What causes checkpoint-inhibitor toxicity?
Autoimmune inflammation. - What treats many significant immune adverse effects from checkpoint inhibitors?
Steroids.
Drugs in this class (2)
All drug classes · Open Antineoplastics (immune checkpoint inhibitors / ICIs) in the interactive console ↗